- Home
- DRUG
as 11-21-2024 4:00pm EST
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
Upcoming Earnings Alert:
Get ready for potential market movements as Bright Minds Biosciences Inc. DRUG prepares to release earnings report on 26 Nov 2024.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 210.7M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 382.4K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.63 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.93 - $79.02 | Next Earning Date: | 11-26-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Bright Minds Biosciences Inc. (DRUG)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Cormorant Asset Management, LP | DRUG | 10% Owner | Oct 15 '24 | Buy | $12.62 | 422,591 | $3,234,386.83 | 690,506 |
Latest Bright Minds Biosciences Inc. News
DRUG Breaking Stock News: Dive into DRUG Ticker-Specific Updates for Smart Investing
GlobeNewswire
13 hours ago
Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting
TipRanks
16 days ago
Bright Minds Biosciences Secures $35 Million Investment
GlobeNewswire
17 days ago
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement
GlobeNewswire
a month ago
Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data
GlobeNewswire
a month ago
Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement
GlobeNewswire
a month ago
Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models
GlobeNewswire
a month ago
Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA™ Technology
MarketWatch
a month ago
Biotech stock tumbles after unexplained 1,446% gain
Compare DRUG vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DRUG Bright Minds Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.